BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sarah Aebersold Sells 5,771 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) insider Sarah Aebersold sold 5,771 shares of BioLife Solutions stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $22.66, for a total value of $130,770.86. Following the completion of the transaction, the insider now directly owns 80,094 shares in the company, valued at $1,814,930.04. This represents a 6.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Sarah Aebersold also recently made the following trade(s):

• On Monday, March 17th, Sarah Aebersold sold 2,695 shares of BioLife Solutions stock. The shares were sold at an average price of $25.44, for a total transaction of $68,560.80.
• On Friday, March 14th, Sarah Aebersold sold 5,632 shares of BioLife Solutions stock. The stock was sold at an average price of $24.96, for a total transaction of $140,574.72.
• On Tuesday, March 11th, Sarah Aebersold sold 1,091 shares of BioLife Solutions stock. The shares were sold at an average price of $25.00, for a total transaction of $27,275.00.
• On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total transaction of $6,484.80.

BioLife Solutions Stock Down 5.9 %

BLFS traded down $1.30 during trading on Tuesday, hitting $20.64. The company had a trading volume of 785,746 shares, compared to its average volume of 367,480. BioLife Solutions, Inc. has a 1-year low of $14.84 and a 1-year high of $29.55. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The company has a market cap of $970.08 million, a PE ratio of -19.47 and a beta of 1.93. The business has a 50-day moving average of $25.43 and a 200-day moving average of $25.41.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.32. The business had revenue of $22.71 million for the quarter, compared to analyst estimates of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same quarter in the prior year, the business posted ($0.21) EPS. As a group, analysts forecast that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on BLFS. Benchmark restated a "buy" rating and set a $30.00 price objective on shares of BioLife Solutions in a research note on Thursday, December 19th. KeyCorp upped their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an "overweight" rating in a report on Friday, December 13th. Northland Securities lifted their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a research note on Wednesday, January 8th. HC Wainwright boosted their target price on shares of BioLife Solutions from $27.00 to $30.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th. Finally, StockNews.com raised shares of BioLife Solutions from a "sell" rating to a "hold" rating in a report on Tuesday. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $31.17.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. D.A. Davidson & CO. lifted its stake in BioLife Solutions by 1.3% during the fourth quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider's stock worth $1,069,000 after purchasing an additional 519 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of BioLife Solutions by 0.7% during the first quarter. Rhumbline Advisers now owns 83,227 shares of the medical equipment provider's stock worth $1,901,000 after purchasing an additional 566 shares during the period. Stifel Financial Corp lifted its position in shares of BioLife Solutions by 5.4% in the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider's stock worth $325,000 after buying an additional 670 shares during the last quarter. 1620 Investment Advisors Inc. boosted its holdings in shares of BioLife Solutions by 41.7% in the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock valued at $60,000 after buying an additional 675 shares during the period. Finally, Smartleaf Asset Management LLC grew its position in shares of BioLife Solutions by 27.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider's stock valued at $117,000 after buying an additional 950 shares during the last quarter. Institutional investors and hedge funds own 93.24% of the company's stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.